Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6287

Provisional Schedule

Committee meeting 12 November 2025
Expected publication 22 April 2026

Project Team

Project lead Greg O'Toole

Email enquiries

External Assessment Group Kleijnen Systematic Reviews Ltd

Stakeholders

Companies sponsors Amgen (sotorasib)
Others Department of Health and Social Care
  NHS England
Patient carer groups Asthma and Lung UK
  Black Health Agency for Equality
  Cancer Black Care
  Helen Rollason Cancer Charity
  Independent Cancer Patients Voice
  Macmillan Cancer Support
  Maggie’s Centres
  Marie Curie
  Oncogene-Driven Lung Cancer Patient Alliance UK
  Roy Castle Lung Cancer Foundation
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Tenovus Cancer Care
  UK Lung Cancer Coalition
Professional groups Association of Cancer Physicians
  Association of Respiratory Nurse Specialists
  British Geriatrics Society
  British Institute of Radiology
  British Oncology Pharmacy Association
  British Psychosocial Oncology Society
  British Society of Interventional Radiology.
  British Thoracic Oncology Group
  British Thoracic Society
  Cancer Research UK
  Lung Cancer and Mesothelioma Clinical Expert Group
  Lung Cancer Nursing UK
  National Heart and Lung Institute
  Primary Care Respiratory Society UK
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society and College of Radiographers
  UK Clinical Pharmacy Association
  UK Oncology Nursing Society
Associated public health groups Public Health Wales
  UK Health Security Agency
Comparator companies Boehringer Ingelheim (nintedanib)
  Bristol-Myers Squibb (adagrasib, subject to NICE evaluation)
  Hospira UK (docetaxel)
  Seacross Pharmaceuticals (docetaxel)
General commentators All Wales Therapeutic and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare Products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Government
  Welsh Health Specialised Services Committee
Relevant research groups Cochrane Lung Cancer Group
  Cochrane UK
  Genomics England
  Institute of Cancer Research
  MRC Clinical Trials Unit
  National Institute for Health Research

Timeline

Key events during the development of the guidance:

Date Update
14 April 2025 Invitation to participate
24 February 2025 - 25 March 2025 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
15 March 2024 Please note that following on from information received from the company, which NICE and NHS England must now consider, further information regarding the timelines for this appraisal will be available in due course. In the meantime, NICE will continue to monitor the situation and will provide an update as and when the situation changes.
16 January 2024 - 13 February 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
16 January 2024 Awaiting development. Status change linked to Topic Selection Decision being set to Selected
16 January 2024 In progress. Draft scope documents issued.

For further information on our processes and methods, please see our CHTE processes and methods manual